Manufacturer
ROCHE DIAGNOSTICS GMBH
Contents
Methoxy polyethylene glycol-epoetin β
Indication
Anaemia associated w/ chronic kidney disease in dialysis & non-dialysis patients.
Instruction
Erythropoiesis stimulating agent (ESA)-naive patient not on dialysis 1.2 mcg/kg SC inj once mthly. Alternatively, 0.6 mcg/kg IV or SC inj once every 2 wk. ESA-naive patient on dialysis 0.6 mcg/kg IV or SC inj once every 2 wk, may be increased by 25-50% of previous dose if rate of rise in Hb <1 g/dL over a mth. ESA-treated patient Start Mircera IV or SC inj once mthly.
Drug interaction
No interaction studies have been performed. The clinical results do not indicate any interaction of MIRCERA with other medicinal products. The effect of other drugs on the pharmacokinetics and pharmacodynamics of MIRCERA was explored using a population analysis approach. There was no indication of an effect of concomitant medications on the pharmacokinetics and pharmacodynamics of MIRCERA.
Malaysia
